| 영문 | histamine | 한글 | 히스타민 |
|---|---|---|---|
| 설명 | 히스타민이란 비만세포과 호염기구라는 세포에 많이 있는 물질로써 기능은 다음과 같다. 1. 모세혈관의 이완과 투과성의 증가 2. 내장에 분포하는 근육의 수축 3. 위산의 분비촉진 4. 심장박동수의 증가 히스타민이 분비되어 다른 세포에 영향을 주어 위와 같은 역할을 하려면 반드시 세포표면에 있는 히스타민 수용체와 결합을 하여야한다. 이 히스타민 수용체에는 두 가지가 있다. 하나는 H1-수용체라고 하는 것인데 이 수용체는 위의 작용중에서 1, 2번의 작용을 매개한다. 즉 H1-수용체에 히스타민이 부착할 때에 위의 1, 2번과 같은 작용이 일어난다. 다른 하나는 H2-수용체라고 하는 것인데 3, 4번의 작용을 매개한다. 그리고 안티히스타민도 각각 H1-수용체에 작용하는 것이 있고, H2-수용체에 작용하는 것이 있다. |
||
| HAP | Handicapped Aid Program; Hazardous Air Pollutants [List]; hazardous air pollution; health alliance p... |
|---|---|
| G3P, | G-3-P glyceraldehyde-3-phosphate; glycerol-3-phosphate |
| GPD | glucose-6-phosphate dehydrogenase; glycerol-phosphate dehydrogenase |
| PD | Doctor of Pharmacy; Dublin Pharmacopoeia; interpupillary distance; Paget disease; pancreatic duct; p... |
| PPP | pain perception profile; palatopharyngoplasty; palmoplantar pustulosis; pentose phosphate pathway; p... |
| P(i) | phosphate and inorganic phosphate |
|---|---|
| Pi | 6-phosphate , inorganic phosphate |
| 4-MH | 4-methyl histamine |
| H | Histamine |
| H2 | Histamine |
| UDPacetylglucosamine-dolichyl-phosphate acetylglucosamine-1-phosphate transferase | <enzyme> Transfers n-acetylglucosamine 1-phosphate from udp-n-acetylglucosamine to dolichyl phosphate, forming n-acetylglucosaminylpyrophosphoryldolichol Chemical name: udp-glcnac-dolichyl-phosphate glcnac-1-phosphate transerase Registry number: EC 2.7.8.15 Synonym: n-acetylglucosamine-1-phosphate transferase, dol-p-p-glcnac synthase, dolichol pathway enzyme I, udp-acetylglucosamine-dolichol phosphate acetylglucosamine-1-phosphate transferase, glcnac-dp-1-phosphotransferase, udp-n-acetyl-d-glucosamine-dolichyl-phosphate n-acetyl-d-glucosaminephosphotransferase, dolichol-p-dependent n-acetylglucosamine-1-phosphate transferase, alg7 gene product (26 Jun 1999) |
|---|---|
| UDP-GlcNAc-undecaprenyl phosphate N-acetylglucosaminyl 1-phosphate transferase | <enzyme> Catalyses transfer of n-acetylglucosamine 1-phosphate from udp-glcnac to undecaprenyl phosphate Registry number: EC 2.7.8.- Synonym: glcnac-p-p-und synthase, gpt enzyme (26 Jun 1999) |
| augmented histamine test | A test for maximal production of gastric acidity or anacidity; after preliminary administration of an antihistamine, histamine acid phosphate is injected subcutaneously in a dose of 0.04 mg/kg of body weight, followed by analysis of gastric contents. Synonym: augmented histamine test. (05 Mar 2000) |
| receptors, histamine | Cell-surface proteins that bind histamine and trigger intracellular changes influencing the behaviour of cells. Histamine receptors are widespread in the central nervous system and in peripheral tissues. Three types have been recognised and designated h1, h2, and h3. They differ in pharmacology, distribution, and mode of action. (12 Dec 1998) |
| receptors, histamine h1 | A class of histamine receptors discriminated by their pharmacology and mode of action. most histamine h1 receptors operate through the inositol phosphate/diacylglycerol second messenger system. Among the many responses mediated by these receptors are smooth muscle contraction, increased vascular permeability, hormone release, and cerebral glyconeogenesis. (12 Dec 1998) |
| receptors, histamine h2 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine h2 receptors act via g-proteins to stimulate adenylate cylase. Among the many responses mediated by these receptors are gastric acid secretion, smooth muscle relaxation, inotropic and chronotropic effects on heart muscle, and inhibition of lymphocyte function. (12 Dec 1998) |
| receptors, histamine h3 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine h3 receptors were first recognised as inhibitory autoreceptors on histamine-containing nerve terminals and have since been shown to regulate the release of several neurotransmitters in the central and peripheral nervous systems. (12 Dec 1998) |
| histamine | <biochemistry> Formed by decarboxylation of histidine. Potent pharmacological agent acting through receptors in smooth muscle and in secretory systems. Stored in mast cells and released by antigen. (See hypersensitivity). Responsible for the early symptoms of anaphylaxis. Also present in some venoms. (18 Nov 1997) |
| histamine agents | Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells. (12 Dec 1998) |
| histamine agonist | Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (12 Dec 1998) |
| histamine antagonists | Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonist. Classical antihistaminics block the histamine h1 receptors only. (12 Dec 1998) |
| histamine-fast | Indicating the absence of the normal response to histamine, especially in speaking of true gastric anacidity. (05 Mar 2000) |
| histamine flush | Vasodilatation and erythema occurring as a result of release of histamine; thought to be a factor in genesis of flush of carcinoid syndrome. (05 Mar 2000) |
| histamine h1 antagonists | Drugs that selectively bind to but do not activate histamine h1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonise or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system h1 receptors are not as well understood. (12 Dec 1998) |
| histamine h2 antagonists | Drugs that selectively bind to but do not activate histamine h2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|